SGLT2抑制剂对2型糖尿病患者血糖、血尿酸水平及心脏功能的影响.

Objective: To study the effects of SGLT2 inhibitors on blood glucose, blood uric acid levels and heart function in patients with type 2 diabetes. Methods: A total of 106 patients with type 2 diabetes combined with stable cardiac insufficiency admitted to our hospital from January 2019 to June 2020 were selected as the research objects. The patients were divided into two groups by random number table method. All patients were given diet control and exercise therapy for type 2 diabetes, and symptomatic drug therapy for cardiac insufficiency. Control group was additively given metformin, and observation group was additively given the SGLT2 inhibitordagliazin. Blood glucose, blood uric acid, BNP level, heart function and quality of life in 2 groups were compared. Results: There were no significant differences in the levels of PBG, FBG and HBAIC in 2 groups before treatment（P>0.05). After treatment, the above indexes in 2 groups were significantly decreased, and the observation group was significantly lower than the control group（P<0.05). There was no significant difference in UA and BNP levels between 2 groups before treatment（P>0.05). After treatment, the above indexes in 2 groups were significantly decreased, and the observation group was significantly lower than the control group（P<0.05). Before treatment, there was no statistical difference in LVEF and LVEDD levels between the two groups（P>0.05). After treatment, LVEF level in the observation group was significantly increased while LVEDD level was significantly decreased, and there was a statistical difference between the two groups（P<0.05). However, there was no statistical difference between the control group before and after treatment（P>0.05). There was no statistical difference in the SF-36 score between the two groups before treatment（P>0.05）, but after treatment, the SF-36 score of the two groups was significantly increased, and the observation group was significantly higher than the control group（P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups（P>0.05). Conclusion: Daglixin can significantly improve the levels of blood glucose and uric acid in patients with type 2 diabetes mellitus complicated with stable cardiac insufficiency, and can also improve the cardiac function of patients, which is worthy of clinical reference. [ABSTRACT FROM AUTHOR]